Press release
Global Adalimumab, Infliximab and Etanercept Biosimilars Market Share to Reach $7.44 Billion by 2029, Growing at 10.5% CAGR
Adalimumab, Infliximab and Etanercept Biosimilars
The advent of biosimilars into the adalimumab, infliximab, and etanercept market has been due to the patent expiration of their branded counterparts. For instance, on the expiry of the patent for the Remicade brand, the FDA in the United States sanctioned the use of Inflectra, a biosimilar developed by Hospira (a Pfizer Inc. subsidiary), for the treatment of several autoimmune diseases, such as rheumatoid arthritis, adult ulcerative colitis, and plaque psoriasis. Similar situations occurred when the EU patent for Amgen's Enbrel expired, paving the way for the European Commission to approve Benepali, a biosimilar of Enbrel. The expiration of Humira's patent also allowed its biosimilars to penetrate the market, with the FDA most recently giving the green light to Hulio, the sixth Humira biosimilar. Thus, the expiration of patents for branded biologic drugs like Humira, Enbrel, and Remicade is likely to fuel the demand for adalimumab, infliximab, and etanercept biosimilars.
Get Your Adalimumab, Infliximab and Etanercept Biosimilars Market Report Here:
https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilar-global-market-report
How will the growth rate of the adalimumab, infliximab and etanercept biosimilars market shape industry trends by 2034?
The market size for biosimilars of adalimumab, infliximab and etanercept has significantly expanded in the past few years. There's a projected growth from $4.37 billion in 2024 to $4.98 billion in 2025, representing a compound annual growth rate (CAGR) of 14.1%. The substantial growth during the previous period can be associated with an upsurge in healthcare spending, alterations in regulations, government-led initiatives and escalating healthcare expenses.
Projected to accelerate in the coming years, the adalimumab, infliximab, and etanercept biosimilars market is anticipated to expand to $7.44 billion by 2029, maintaining a compound annual growth rate (CAGR) of 10.5%. The augmentation during the predicted period can be accredited to the escalation in healthcare expenditures, demographic aging and enhanced healthcare accessibility, which are all significant contributors to market advancement. The forecast period is expected to be characterized by a concentration on the introduction of innovative products, emphasis on mergers and acquisitions, a dedication to forming strategic partnerships, and an intention to boost investments.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp
What trends are poised to drive the future success of the adalimumab, infliximab and etanercept biosimilars market?
Major firms active in the adalimumab, infliximab, and etanercept biosimilars market are putting their efforts into producing novel products like citrate-free adalimumab, aiming to offer dependable customer services. As the name implies, citrate-free adalimumab is a version of the biological drug adalimumab without citrate. For instance, Fresenius Kabi, a German company specializing in pharmaceuticals and healthcare technologies pertaining to infusion, transfusion, and clinical nutrition, secured FDA approval for their biosimilar product Idacio (adalimumab) in December 2022. This product, geared towards managing chronic autoimmune disorders, has been designed for all allowable uses of the reference product. Advanced analytical methods have been utilized in its development for the treatment of a variety of chronic conditions.
Which primary segments of the adalimumab, infliximab and etanercept biosimilars market are driving growth and industry transformations?
The adalimumab, infliximab and etanercept biosimilars market covered in this report is segmented -
1) By Product: Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications
Subsegments:
1) By Adalimumab Biosimilars: Amjevita (Amgen), Hyrimoz (Sandoz), Cyltezo (Boehringer Ingelheim), Others
2) By Infliximab Biosimilars: Inflectra (Pfizer), Remsima (Celltrion), Ixifi (Pfizer), Others
3) By Cipleumab: Cipleumab Biosimilars, Other Biosimilars in Development
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3473
Which geographical regions are pioneering growth in the adalimumab, infliximab and etanercept biosimilars market?
North America was the largest region in the adalimumab, infliximab, and etanercept biosimilars market in 2024. The regions covered in the adalimumab, infliximab, and etanercept biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Who are the influential players reshaping the adalimumab, infliximab and etanercept biosimilars market landscape?
Major companies operating in the adalimumab, infliximab and etanercept biosimilars market include Biogen, Novartis (Sandoz), Pfizer, Amgen, Celltrion, Samsung Bioepis (Samsung Biologics), Hetero Drugs Limited, Fresenius Kabi AG, Boehringer Ingelheim, Biocon, Zydus Lifesciences Limited, Reliance Life Sciences, Torrent Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Cipla Limited, Zhejiang Hisun Pharmaceutical Co. Ltd, Bio-Thera Solutions, Ltd, Innovent Biologics (Suzhou) Co. Ltd, Janssen Biologics BV, Shanghai CP Guojian Pharmaceutical Co. Ltd, Sansheng Guojian, Shanghai Junshi Biosciences Co. Ltd, Mabwell Bioscience Co. Ltd, LG Chem, Nippon Kayaku, Mochida Pharmaceutical Co. Ltd, mAbxience, Allergan, Microgen, Geropharm, Valenta, NovaMedica Veropharm, Biocad, Roche, Bristol-Myers Squibb, Celon Pharma, SynBio, Ache, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Mylan, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty) Ltd
Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp
What Is Covered In The Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report?
•Market Size Forecast: Examine the adalimumab, infliximab and etanercept biosimilars market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the adalimumab, infliximab and etanercept biosimilars market for a structured understanding.
•Key Players Overview: Analyze major players in the adalimumab, infliximab and etanercept biosimilars market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the adalimumab, infliximab and etanercept biosimilars market.
•Segment Contributions: Evaluate how different segments drive overall growth in the adalimumab, infliximab and etanercept biosimilars market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the adalimumab, infliximab and etanercept biosimilars market.
•Industry Challenges: Identify potential risks and obstacles affecting the adalimumab, infliximab and etanercept biosimilars market.
•Competitive Landscape: Review strategic developments in the adalimumab, infliximab and etanercept biosimilars market, including expansions, agreements, and new product launches.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Adalimumab, Infliximab and Etanercept Biosimilars Market Share to Reach $7.44 Billion by 2029, Growing at 10.5% CAGR here
News-ID: 3898013 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Bio
Human Plasma Products Market 2023: Industry Future Trends | Takeda, CSL, Grifols …
The Human Plasma Products market research report is proficient and top to bottom research by specialists on the current state of the industry. This statistical surveying report gives the most up to date industry information and industry future patterns, enabling you to distinguish the items and end clients driving income development and benefit. It centres around the real drivers and restrictions for the key players and present challenge status with…
Gene Therapy Products Market | Advantagene, Avalanche Bio, Bluebird Bio, Cellado …
The global gene therapy products market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the gene therapy products market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
Bio-based Polymethyl Methacrylate (Bio-PMMA) Market 2023 | Detailed Report
The Bio-based Polymethyl Methacrylate (Bio-PMMA) report compiles the market information depending upon market development and growth factors, optimizing the growth path. In addition, it highlights the strategies and market share of the leading vendors in the particular market. The report follows a robust research methodology model that helps to make informed decisions. It obtains both qualitative and quantitative market information supported by primary research.
The Bio-based Polymethyl Methacrylate (Bio-PMMA) research report…
Bio Pharma Buffer Market – A comprehensive study by Key Players: Bio-Rad, Lonz …
Latest Market intelligence report released by HTF MI with title "COVID-19 Outbreak-Global Bio Pharma Buffer Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020" is designed covering micro level of analysis by manufacturers and key business segments. The COVID-19 Outbreak-Global Bio Pharma Buffer Market survey analysis offers energetic visions to conclude and study market size, market hopes, and competitive surroundings. The research is derived through primary and secondary…
IVIG Market Anticipated a Noteworthy CAGR during 2019-2024 & Companies Included …
A report added to the rich database of Qurate Business Intelligence, titled “World IVIG Market by Product Type, Players and Regions - Forecast to 2024”, provides a 360-degree overview of the Global market. Approximations associated with the market values over the forecast period are based on empirical research and data collected through both primary and secondary sources. The authentic processes followed to exhibit various aspects of the market makes the…
Green & Bio-based Solvents Market Analysis, Demand, & Opportunities till 2023 | …
A latest research report titled as “Green & Bio-based Solvents Market for Paints & Coatings, Printing Inks, Commercial & Domestic Cleaning, Adhesives & Sealants, Pharmaceutical, Cosmetics, and Other Applications - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023” has been recently added to the vast portfolio of Market Research Reports Search Engine (MRRSE) online research offerings. This report is a professional and in-depth analysis on the…
